RxDoctor Payments Data

Courtney Jacobs, APRN

Family · Centerville, OHNPI 1255976205

Payments from drug & device makers

$11,494in general payments, 2019–2025

Across 546 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Johnson & Johnson$772
  • Lilly USA, LLC$722
  • Bayer$513
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$11,35399%
  • Education$1281%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,494 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$37,798
Medicare patients
157
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$70,216
EliquisApixaban59$66,752
OzempicSemaglutide44$64,364
MounjaroTirzepatide36$55,964
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$43,536
FarxigaDapagliflozin Propanediol30$42,005
RybelsusSemaglutide23$40,885
JanuviaSitagliptin Phosphate46$36,273
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$27,012
MyrbetriqMirabegron15$16,032
Janumet XrSitagliptin Phos/Metformin Hcl21$12,922
XareltoRivaroxaban13$8,919
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$7,690
LinzessLinaclotide13$7,551
XanaxAlprazolam11$7,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,466$105,24967 claims
Boehringer IngelheimJardiance$193$70,21660 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,545$69,01758 claims
PfizerEliquis$207$66,75259 claims
Lilly USA, LLCMounjaro$722$55,96436 claims
MerckJanuvia, Janumet Xr$150$49,19567 claims
GSKTrelegy Ellipta$76$43,53643 claims
Astellas Pharma US IncMyrbetriq$242$16,03215 claims
Johnson & JohnsonXarelto$772$8,91913 claims
AbbVieLinzess, Synthroid$2,198$8,73753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →